Cost-effectiveness of therapeutic drug monitoring (TDM) of biologic treatment in rheumatic diseases: a narrative review

References

• Mabilat C, Gros MF, Nicolau D, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis. 2020;39(5):1–13. doi: 10.1007/s10096-019-03769-8.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834. doi: 10.1053/j.gastro.2017.07.032.
   PubMed Web of Science ®Google Scholar
• Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–1053. doi: 10.1111/apt.14368.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Tsai WC, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16–e16. doi: 10.1136/annrheumdis-2013-203893.
   PubMed Web of Science ®Google Scholar
• van Bezooijen JS, Koch BCP, van Doorn MBA, et al. Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations. Ther Drug Monit. 2016;38(4):432–438. doi: 10.1097/FTD.0000000000000310.
   PubMed Web of Science ®Google Scholar
• l‘Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484–487. doi: 10.1136/annrheumdis-2017-211781.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817–821. doi: 10.1136/ard.2009.112847.
   PubMed Web of Science ®Google Scholar
• Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, et al. Optimal concentration range of golimumab in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2018;36:110–114.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, van Tubergen A, Gehin J, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):65–73. doi: 10.1136/annrheumdis-2022-222155.
   PubMed Web of Science ®Google Scholar
• Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol. 2017;69(1):108–113. doi: 10.1002/art.39841.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–926. doi: 10.1136/ard.2006.065615.
   PubMed Web of Science ®Google Scholar
• Kernick D. Introduction of health economics for the medical practitioner. Postgrad Med J. 2003;79(929):147–150. doi: 10.1136/pmj.79.929.147.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumour necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2011–2019. doi: 10.1002/art.39169.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, CHEERS 2022 ISPOR Good Research Practices Task Force., et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health. BMJ. 2022;376:e067975. doi: 10.1136/bmj-2021-067975.
   PubMedGoogle Scholar
• Syversen S, Goll G, Jorgensen K, et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomized, controlled, open, parallel group, phase IV study (the nor-DRUM study). Trials. 2020;21(1):13. doi: 10.1186/s13063-019-3734-4.
   PubMed Web of Science ®Google Scholar
• Rombach I, Tillet W, Jadon D, et al. Treating to target in psoriatic arthritis: assessing real-world outcomes and optimizing therapeutic strategy for adult with psoriatic arthritis – study protocol for the MONITOR-PsA study, a trial within cohorts study design. Trials. 2021;22(1):185. doi: 10.1186/s13063-021-05142-7.
   PubMed Web of Science ®Google Scholar
• Krieckaert C, Nair S, Nurmohamed M, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361–368. doi: 10.1136/annrheumdis-2013-204101.
   PubMed Web of Science ®Google Scholar
• Laine J, Jokiranta T, Eklund K, et al. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-a blockers. Biol: Targets Ther. 2016;10:67–73.
   PubMedGoogle Scholar
• Gómez-Arango C, Gorostiza I, Úcar E, et al. Cost-Effectiveness of therapeutic drug monitoring-guided adalimumab therapy in rheumatic diseases: a prospective, pragmatic trial. Rheumatol Ther. 2021;8(3):1323–1339. doi: 10.1007/s40744-021-00345-5.
   PubMed Web of Science ®Google Scholar
• Laar C, Voshaar M, Fakhouri W, et al. Cost-effectiveness of a JAK1/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. Clinicoecon Outcomes Res. 2020;12:213–222. doi: 10.2147/CEOR.S231558.
   PubMed Web of Science ®Google Scholar
• Ucar E, Gorostiza Í, Gόmez C, et al. Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases. Prelim Res INGEBIO Study Annals Rheum Dis. 2017;76:826.
   Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Gonzalez del Valle L, et al. THU0189 therapeutic drug monitoring (TDM) in rheumatic day clinic enables to reduce pharmaceutical cost maintaining clinical efficacy. Ann Rheum Dis. 2013;72(Suppl 3):A227–A227. doi: 10.1136/annrheumdis-2013-eular.717.
   Google Scholar
• Kim Y, Kim S, Park J, et al. Clinical response and hospital costs of therapeutic drug monitoring for vancomycin in elderly patients. J Pers Med. 2022;12(2):163. doi: 10.3390/jpm12020163.
   PubMed Web of Science ®Google Scholar
• Cheifetz A. Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease. Gastroen Hepatol. 2017;13(9):1–4.
   Google Scholar
• Marquez-Megias S, Nalda-Molina R, Sanz-Valero J, et al. Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review. Pharmaceutics. 2022;14(5):1009. doi: 10.3390/pharmaceutics14051009.
   PubMed Web of Science ®Google Scholar
• Tikhonova IA, Yang H, Bello S, et al. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2021;25(8):1–248. doi: 10.3310/hta25080.
   PubMed Web of Science ®Google Scholar
• Martelli L, Olivera P, Roblin X, et al. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017;52(1):19–25. doi: 10.1007/s00535-016-1266-1.
   PubMed Web of Science ®Google Scholar
• Woods AM, Mara KC, Rivera CG. Clinical pharmacists’ interventions and therapeutic drug monitoring in patients with mycobacterial infections. J Clin Tuberc Other Mycobact Dis. 2023;30:100346. doi: 10.1016/j.jctube.2023.100346.
   PubMedGoogle Scholar